DGAP-News: aap's transformation continues: Marc Langner strengthens Supervisory Board

aap Implantate AG ("aap" or the "Company") announces a change in the composition of its Supervisory Board.

Information
Content
Key Points: 
  • aap Implantate AG ("aap" or the "Company") announces a change in the composition of its Supervisory Board.
  • As part of aap's further transformation, Mr. Marc Langner (45) will strengthen the Company's supervisory body with effect from 1 November 2021.
  • "Marc Langner can look back on many years in various board and management positions," says Dr. med.
  • Mr. Langner succeeds by way of court appointment Mr. Biense Visser (69), who will resign from his office as a member of aap's Supervisory Board for personal reasons.



DGAP-News: aap Implantate AG

/ Key word(s): Personnel


aap's transformation continues: Marc Langner strengthens Supervisory Board

14.10.2021 / 10:06

The issuer is solely responsible for the content of this announcement.


aap Implantate AG ("aap" or the "Company") announces a change in the composition of its Supervisory Board. As part of aap's further transformation, Mr. Marc Langner (45) will strengthen the Company's supervisory body with effect from 1 November 2021. Marc Langner is the founder and CEO of a listed investment company specializing in venture capital financing. He has many years of experience in management positions at various companies and has extensive professional experience in the areas of corporate finance, capital markets and corporate law as well as strategic support for growth companies. Among other things, he worked for one of the Big Four consulting firms in transaction consulting and enterprise valuation and was a member of the Board of Directors of a Swiss-based FinTech company for several years.

"Marc Langner can look back on many years in various board and management positions," says Dr. med. Nathalie Krebs, Chairwoman of aap's Supervisory Board. "He is a proven expert in the fields of corporate finance and M&A and additionally has an excellent network. We are very much looking forward to working with him and are sure that aap will benefit from his extensive experience and distinctive financing and transaction competencies."

 

Mr. Langner succeeds by way of court appointment Mr. Biense Visser (69), who will resign from his office as a member of aap's Supervisory Board for personal reasons. His office will end with effect from 31 October 2021. Biense Visser was first elected to the Company's Supervisory Board by the Annual General Meeting in the financial year 2014 and held the position of Chairman until 2019. Previously, Mr. Visser was aap's CEO from 2009 to 2014.

 

"Biense Visser has served aap since 2009 in different roles with enthusiasm and dedication," comments Dr. med. Nathalie Krebs. "As a real team player, he has significantly contributed to aap's transformation from a diversified medical technology company to a pure player in trauma. On behalf of the Supervisory Board, the Management Board, and the entire staff of aap, I would like to express my sincere thanks to Mr. Visser for his commitment and the work he has done for the Company over more than a decade."

 

Mr. Visser comments the change in the Supervisory Board as follows: "The application of aap's silver coating technology in trauma will make the world a better place for many patients around the globe. I want to thank all stakeholders of aap for their continued support of this innovative strategy. As aap now enters the next phase of its transformation, now is a good time for me personally to make room for new talents and competencies."



 

----------------------------------------------------------------

aap
Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The Company develops, manufactures and markets products for trauma. The IP-protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as the antibacterial silver coating technology and magnesium-based implants. These technologies address critical and unmet needs in trauma. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups, and hospital groups, while at international level it primarily uses a broad network of distributors in around 25 countries. In the US the Company pursues a hybrid distribution strategy with its subsidiary aap Implants Inc. Distribution is carried out both through distribution agents and partnerships with global orthopedic companies. aap Implantate AG's stock is listed in the General Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit our website at www.aap.de.

Forward-looking statement

This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

 

For queries, please contact:

aap Implantate AG; Fabian Franke; Head of Investor Relations; Lorenzweg 5; 12099 Berlin, Germany; Phone: +49 (0)30 75019 - 134; Fax: +49 (0)30 75019 - 290; Email: f.franke@aap.de




14.10.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Germany
Phone: +49 (0) 30 75 01 90
Fax: +49 (0) 30 75 01 91 11
E-mail: info@aap.de
Internet: www.aap.de
ISIN: DE000A3H2101
WKN: A3H210
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1240700



 
End of News DGAP News Service

1240700  14.10.2021 

fncls.ssp?fn=show_t_gif&application_id=1240700&application_name=news&site_id=jotup